In a bid to make bulk drugs for cardiac, anti-infectives, anti-tuberculosis, neurology and other segments, Lupin is reportedly planning to expand its Vadodara facility. In this regard, the company will invest around Rs 270 crore.
The Dabhasa plant of Lupin near Vadodara is one of the leading bulk drug manufacturing sites for the company. The Dabhasa plant is one of our major active pharmaceutical ingredient manufacturing sites which also exports. It is a US Food and Drug Administration (USFDA) approved facility.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 2000.75 |
| Dr. Reddys Labs. | 1144.35 |
| Cipla | 1466.00 |
| Lupin | 2419.10 |
| Zydus Lifesciences | 1115.50 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: